DUBLIN–(BUSINESS WIRE)–The “Diagnostic Specialty Antibodies Market by Type, Clonality, Technique, Conjugate, and Application – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The diagnostic specialty antibodies market is expected to grow at a CAGR of 4.6% from 2022-2029 to reach $39.99 billion by 2029.
Following a comprehensive primary and secondary research and an in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth of the diagnostic specialty antibodies market is mainly attributed to the growing prevalence of diseases worldwide and the burden imposed on the people by these diseases, the rising incidences of unintended pregnancies, the increasing availability of funding for researchers with the use of diagnostic antibodies, and the increasing number of regulatory approvals of test kits containing diagnostic antibodies.
In addition to this, the high prevalence of diseases in emerging countries and the growing number of initiatives by public and private organizations supporting diagnosis activities to eradicate infectious diseases are expected to provide significant opportunities for the growth of this market during the forecast period.
An in-depth analysis of the geographical scenario of the diagnostic specialty antibodies market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.
North America is estimated to command the largest share of the diagnostic specialty antibodies market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The increasing number of regulatory approvals and launches of antibodies and test kits containing diagnostic antibodies in the region and the high burden of infectious diseases and cancer are the major factors driving the growth of this market in North America. Moreover, the growing availability of research funding for diseases such as cancer, Alzheimer’s, and COVID-19 have further strengthened the market in the region.
Market Insights
Drivers
- High Burden of Infectious and Chronic Diseases Globally
- Increasing Funding for Clinical Trials and Research
- Increasing Use of Immunoassays in Oncology
- Technological Advancements in Immunoassays
- Growing Demand for Pregnancy Testing Owing to Self-testing and Restricted Use of Contraceptives
Restraints
- Use of Substitute Tests for Diagnosis
- The Availability of Vaccines for Diseases Like Hepatitis, Tuberculosis, Influenza, Malaria, and Dengue
Opportunities
- Initiatives by Public and Private Organizations to Increase Diagnostic Testing
- Emerging Economies
Challenges
- Misleading Results With Antibody Tests
- High Cost of Manufacturing Antibodies
Scope of the Report:
Global Diagnostic Specialty Antibodies Market, by Type
- Primary Antibodies
- Secondary Antibodies
Global Diagnostic Specialty Antibodies Market, by Clonality
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
Global Diagnostic Specialty Antibodies Market, by Technique
- ELISA
- Lateral Flow Assay
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
- Immunocytochemistry (ICC)
- Other Techniques
Global Diagnostic Specialty Antibodies Market, by Conjugate
- Conjugated Antibodies
- Unconjugated Antibodies
Global Diagnostic Specialty Antibodies Market, by Application
- Infectious Diseases
- Respiratory Infections
- COVID-19
- Influenza
- Tuberculosis (TB)
- Pneumonia
- Other Respiratory Infections
- Parasitic Infections
- Dengue
- Malaria
- Other Parasitic Infections
- Gastrointestinal Infections (GI Infections)
- Salmonellosis
- E. Coli Infections
- Other GI Infections
- Blood Borne Diseases
- Hepatitis
- HIV
- Other Blood Borne Infections
- Other Infectious Diseases
- Oncology
- Pregnancy Detection/Fertility Testing
- Other Applications
Global Diagnostic Specialty Antibodies Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Companies Mentioned
- Abcam plc (U.K.)
- F. Hoffman La Roche Ltd. (Switzerland)
- Bio-Rad Laboratories Inc. (U.S.)
- Creative Diagnostics (U.S.)
- Merck KGaA (Germany)
- Agilent Technologies Inc. (U.S.)
- Becton Dickinson and Company (U.S.)
- Rockland Immunochemicals Inc. (U.S.)
- Santa Cruz Biotechnology (U.S.)
- Novus Biologicals LLC (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
For more information about this report visit https://www.researchandmarkets.com/r/12rp7i
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900